Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

The primary objective of this specimen correlative study was two-fold: to provide a mechanism for the association of known molecular alterations with clinical outcomes, and to provide rapid genetic profiling of alterations with known clinical utility using tumor and germline specimens to support treatment decisions.

Authorized Access
Publicly Available Data (Public ftp)
Study Inclusion/Exclusion Criteria

Inclusion Criteria:
1.Current or prospective cancer patients; current cancer patients must have histologically or cytologically confirmed diagnosis of cancer

2.Tumor tissue available and suitable for molecular analyses from at least one of the following sources:

  • Tissue previously stored in UNC's Tissue Procurement Facility (TPF)
  • Tissue previous stored at an institution other than UNC-CH, provided investigators can determine that the tumors were sampled and stored under appropriate conditions for inclusion in the study
  • Patient undergoing tissue collection as per clinical standard of care and willing to allow specimens from surplus tissue to be diverted for research purposes
  • Patient undergoing tissue collection as per clinical standard of care and willing to have additional specimens taken for research
  • Patient willing to undergo biopsy for purpose of research only

Exclusion Criteria:

  • Any condition that would make participation in the protocol unreasonably hazardous for the patient in the opinion of the treating physician
  • Affected by dementia, altered mental status, or any psychiatric or co-morbid condition that would prohibit the understanding or rendering of informed consent

Molecular Data
TypeSourcePlatformNumber of Oligos/SNPsSNP Batch IdComment
Captured DNA Sequencing Illumina HiSeq 2000 N/A N/A
Captured DNA Sequencing Illumina HiSeq 2500 N/A N/A
Captured DNA Sequencing Illumina NextSeq 500 N/A N/A
Captured DNA Sequencing Illumina HiSeq 4000 N/A N/A
Study History

September 2011: study start
June 2018: study completion

Selected publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Resources
Authorized Data Access Requests
See research articles citing use of the data from this study
Study Attribution
  • Principal Investigator
    • H. Shelton Earp, MD. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Funding Source
    • University Cancer Research Fund (UCRF), Chapel Hill, NC, USA.
    • National Cancer Institute (NCI), Bethesda, MD, USA.